ADC Therapeutics
Latest round
- Series E
Last raised
- Oct 2017
Total raised
- $280M
Investors
- 5
About ADC Therapeutics
Founded in 2011 and based in Lausanne, Switzerland, ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company with research and development operations in London, clinical and commercial operations in New Jersey, and CMC (chemistry, manufacturing and controls) operations in the San Francisco Bay Area. The company was founded by Chief Executive Officer and Director Chris Martin, former co-founder of Spirogen Ltd. who led numerous collaboration transactions, including agreements with Genentech and Seattle Genetics. Also, the company became a public entity in May 2020 where Deerfield Partners provided USD 65 million convertible senior notes to support its growth. The firm focuses on the development and commercialization of highly potent and targeted antibody-drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The company's product candidates include loncastuximab tesirine-lpyl, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, and ADCT-701.
Who invested in ADC Therapeutics
5 investors across 2 rounds
See all investors in ADC Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ADC Therapeutics
Who invested in ADC Therapeutics?
ADC Therapeutics has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ADC Therapeutics raised?
ADC Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ADC Therapeutics last raise money?
ADC Therapeutics's most recent round on record is a Series E, in Oct 2017.
What does ADC Therapeutics do?
Founded in 2011 and based in Lausanne, Switzerland, ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company with research and development operations in London, clinical and commercial operations in New Jersey, and CMC (chemistry, manufacturing and controls) operations in the San Francisco Bay Area.
Where is ADC Therapeutics headquartered?
ADC Therapeutics is headquartered in Lausanne, Switzerland.
Which VCs invest in companies like ADC Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at ADC Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like ADC Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.